News & Updates
Filter by Specialty:
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
Evaluation and treatment rates of patients with chronic hepatitis B (CHB) remain poor worldwide and differ by sex and race or ethnicity, reports a real-world study.
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
19 Jul 2024
Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease
In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).
Nirmatrelvir-ritonavir bests molnupiravir in COVID-19 patients with advanced kidney disease
18 Jul 2024
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
10 Jul 2024
9-month, oral modified treatment regimens make the grade in drug-resistant TB
Nine-month, fully oral modified short treatment regimens (mSTRs) consisting of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine or delamanid appear to yield high treatment success and good safety results in the treatment of patients with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis (TB), according to a study.
